Substance use by liver transplant candidates: An anonymous urinalysis study

Liver Transplantation

Volumn 17, Issue 10, 2011, Pages 1200-1204

  Webzell, Ian ^a   Ball, David ^b   Bell, James ^b   Sherwood, Roy A ^a   Marsh, Andrew ^a   O'Grady, John G ^a   Heaton, Nigel D ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CANNABIS; COCAINE; CODEINE; DIHYDROCODEINE; ETHYL GLUCURONIDE; ETHYL SULFATE; METHADONE; MORPHINE; OPIATE; SULFATE; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SUBSTANCE ABUSE; TOXICITY TESTING; URINALYSIS;

ADULT; AGED; ALCOHOL DRINKING; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER TRANSPLANTATION; LONDON; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PREVALENCE; SELF REPORT; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; URINALYSIS;

EID: 80053233615     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22370     Document Type: Article

References (33)

1. Tome S, Wells JT, Said A, Lucey MR,. Quality of life after liver transplantation. A systematic review. J Hepatol 2008; 48: 567-577.
2. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L,. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. Liver Transpl 2004; 10: 886-897. (Pubitemid 38979259)
3. Dawwas MF, Gimson AE, Lewsey JD, Copley LP, van der Meulen JH,. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States. Gut 2007; 56: 1606-1613. (Pubitemid 350033202)
4. Pomfret EA, Fryer JP, Sima CS, Lake JR, Merion RM,. Liver and intestine transplantation in the United States, 1996-2005. Am J Transplant 2007; 7 (pt 2): 1376-1389. (Pubitemid 46606941)
5. Perut V, Conti F, Scatton O, Soubrane O, Calmus Y, Vidal-Trecan G,. Might physicians be restricting access to liver transplantation for patients with alcoholic liver disease? J Hepatol 2009; 51: 707-714.
6. Neuberger J, Adams D, MacMaster P, Maidment A, Speed M,. Assessing priorities for allocation of donor liver grafts: survey of public and clinicians. BMJ 1998; 317: 172-175. (Pubitemid 28325540)
7. Kotlyar DS, Burke A, Campbell MS, Weinrieb RM,. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103: 734-743. (Pubitemid 351405998)
8. Liver Advisory Group. UK Liver Transplant Group recommendations for liver transplant assessment in the context of alcohol-related liver disease. Accessed June 2011.
9. Liver Advisory Group. UK Liver Transplant Group recommendations for liver transplant assessment in the context of illicit drug use. Accessed June 2011.
10. Weinrieb RM, Van Horn DH, Lynch KG, Lucey MR,. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl 2011; 17: 539-547.
11. Iasi MS, Vieira A, Añez CI, Trindade R, Codovani NT, Favero SS, et al. Recurrence of alcohol ingestion in liver transplantation candidates. Transplant Proc 2003; 35: 1123-1124. (Pubitemid 36555313)
12. Erim Y, Böttcher M, Dahmen U, Beck O, Broelsch CE, Helander A,. Urinary ethyl glucuronide testing detects alcohol consumption in alcoholic liver disease patients awaiting liver transplantation. Liver Transpl 2007; 13: 757-761. (Pubitemid 46796549)
13. Carbonneau M, Jensen LA, Bain VG, Kelly K, Meeberg G, Tandon P,. Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl 2010; 16: 91-97.
14. Helander A, Böttcher M, Fehr C, Dahmen N, Beck O,. Detection times for urinary ethyl glucuronide and ethyl sulfate in heavy drinkers during alcohol detoxification. Alcohol Alcohol 2009; 44: 55-61.
15. Walsham NE, Sherwood RA,. Ethyl glucuronide. Ann Clin Biochem. In press.
16. Schmitt G, Aderjan R, Keller T, Wu M,. Ethyl glucuronide: an unusual ethanol metabolite in humans. Synthesis, analytical data, and determination in serum and urine. J Anal Toxicol 1995; 19: 91-94.
17. Helander A, Dahl H,. Urinary tract infection: a risk factor for false-negative urinary ethyl glucuronide but not ethyl sulfate in the detection of recent alcohol consumption. Clin Chem 2005; 51: 1728-1730. (Pubitemid 41233114)
18. Baranowski S, Serr A, Thierauf A, Weinmann W, Grosse Perdekamp M, Wurst FM, Halter CC,. In vitro study of bacterial degradation of ethyl glucuronide and ethyl sulphate. Int J Legal Med 2008; 122: 389-393.
19. Armbruster DA, Hubster EC, Kaufman MS, Ramon MK,. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening. Clin Chem 1995; 41: 92-98.
20. Helander A, Beck O,. Ethyl sulfate: a metabolite of ethanol in humans and a potential biomarker of acute alcohol intake. J Anal Toxicol 2005; 29: 270-274. (Pubitemid 41191694)
21. Stephanson N, Dahl H, Helander A, Beck O,. Direct quantification of ethyl glucuronide in clinical urine samples by liquid chromatography-mass spectrometry. Ther Drug Monit 2002; 24: 645-651.
22. Wurst FM, Wiesbeck GA, Metzger JW, Weinmann W,. On sensitivity, specificity, and the influence of various parameters on ethyl glucuronide levels in urine-results from the WHO/ISBRA study. Alcohol Clin Exp Res 2004; 28: 1220-1228. (Pubitemid 39108620)
23. Dancygier H, Strassburg CP,. Hepatic drug metabolism and drug toxicity. In:, Dancygier H, ed. Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Vol 2. New York, NY: Springer; 2009: 1211-1222.
24. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M,. Hepatic encephalopathy: a review. Ann Hepatol 2003; 2: 122-130.
25. Herz A,. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl) 1997; 129: 99-111. (Pubitemid 27033665)
26. Koob GF, Nestler EJ,. The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci 1997; 9: 482-497. (Pubitemid 27363951)
27. Galanter M, Dermatis H, Mansky P, McIntyre J, Perez-Fuentes G,. Substance-abusing physicians: monitoring and twelve-step-based treatment. Am J Addict 2007; 16: 117-123. (Pubitemid 46633923)
28. Kleinpeter CB, Brocato J, Koob JJ,. Does drug testing deter drug court participants from using drugs or alcohol? J Offender Rehabil 2010; 49: 434-444.
29. DiMartini A, Day N, Lane T, Beisler AT, Dew MA, Anton R,. Carbohydrate deficient transferrin in abstaining patients with end-stage liver disease. Alcohol Clin Exp Res 2001; 25: 1729-1733. (Pubitemid 34033142)
30. Center for Substance Abuse Treatment. The role of biomarkers in the treatment of alcohol use disorders. Accessed June 2011.
31. Haller DL, Acosta MC, Lewis D, Miles DR, Schiano T, Shapiro PA, et al. Hair analysis versus conventional methods of drug testing in substance abusers seeking organ transplantation. Am J Transplant 2010; 10: 1305-1311.
32. Kintz P, Villain M, Cirimele V,. Hair analysis for drug detection. Ther Drug Monit 2006; 28: 442-446. (Pubitemid 44314934)
33. Chapman MH, Kajihara M, Borges G, O'Beirne J, Patch D, Dhillon AP, et al. Severe, acute liver injury and khat leaves. N Engl J Med 2010; 362: 1642-1644.